DOTmed Home MRI Oncology Ultrasound Molecular Imaging X-Ray Cardiology Health IT Business Affairs
News Home Parts & Service Operating Room CT Women's Health Proton Therapy Endoscopy HTMs Mobile Imaging
SEARCH
Current Location:
>
> This Story


Log in or Register to rate this News Story
Forward Printable StoryPrint Comment

 

 

Ultrasound Homepage

China hits back with new tariffs affecting medical imaging equipment More than 5,000 items affected, including X-ray tubes and gamma-ray equipment

FDA greenlights focused ultrasound trial for Alzheimer's treatment Involves temporarily opening the blood-brain barrier

Could AI and 3D printing be the future of OB/GYN ultrasound? Few specialities are equally poised to embrace these cutting edge tools

Healcerion gets FDA nod for wireless ultrasound SONON 300L is 1/10th the cost of traditional systems

All-optical ultrasound could pave way for combined MR-ultrasound imaging Three orders of magnitude faster than current optical systems

MITA calls for timely exemption process for Section 301 tariffs Calls for exemption of medical imaging technology

Dense breast tissue and automated breast ultrasound Understanding what ABUS can mean for the future of diagnosing cancer in dense tissue

KT Corporation and Russian Railways launch Russian digital health system Assist providers in all 173 Russian Railway stations

A rural college producing ultrasound experts Behind the scenes at the Oregon Institute of Technology's ultrasound education program

New model boosts flow efficiency of particle accelerators May lead to smaller accelerators, easier to operate at reduced costs

EDAP TMS SA is now the exclusive
distributor of Theraclion's Echopulse system
in France

Theraclion taps EDAP to distribute HIFU system throughout France

by John R. Fischer , Staff Reporter
Theraclion has chosen EDAP TMS SA to be the exclusive distributor of its Echopulse system in France, as part of a new agreement between the two companies.

The noninvasive ablation solution for breast fibroadenomas and benign thyroid nodules is now available to customers with a new option that allows the system to operate as a mobile pay-per-use solution.

Story Continues Below Advertisement

THE (LEADER) IN MEDICAL IMAGING TECHNOLOGY SINCE 1982. SALES-SERVICE-REPAIR

Special-Pricing Available on Medical Displays, Patient Monitors, Recorders, Printers, Media, Ultrasound Machines, and Cameras.This includes Top Brands such as SONY, BARCO, NDS, NEC, LG, EDAN, EIZO, ELO, FSN, PANASONIC, MITSUBISHI, OLYMPUS, & WIDE.



“We just had approval from the French health care system to actually reimburse our benign breast tumor noninvasive solution,” David Caumartin, CEO of Theraclion, told HCB News. “We wanted to partner with someone who already had a pay-per-use business unit, which was the case with EDAP and therefore, it was natural combination for us to work with them to be able to make an echotherapy standard of care for benign breast tumors.”

The Echopulse system uses EDAP’s proprietary HIFU technology to treat breast fibroadenomas and benign thyroid nodules. Treatment with the system can take between 15 and 45 minutes.

The agreement allows EDAP France to expand the use of HIFU technology outside the field of urology. Through the reimbursement, Theraclion gains ten new sites in France.

The mobile pay-per-use solution will assist in the quick implementation of the Forfait Innovation cost-effectiveness study, which compares Echopulse echotherapy to surgery in the treatment of breast fibroadenoma, and will enable quick access among patients to thyroid echotherapy.

“Theraclion is the only one that can propose noninvasive ablation for benign thyroid and benign breast tumors,” he said. “We are proposing this in an outpatient fashion, without general anesthetic, just local. We basically destroy soft tissue lesions in 15, 30, 45 minutes of treatment time in a single session.”

Theraclion’s echotherapy procedure was recently was listed on the website of the British National Institute for Health and Clinical Excellence with guidance on its interventional procedures program (IPP) for the noninvasive treatment of breast fibroadenoma, and also received regulatory approval from the Russian Ministry of Health.

The system has been CE marked since 2012 and is available in Europe and Asia with key markets in Germany and Hong Kong. It is currently undergoing two clinical trials at four sites in the U.S.

Ultrasound Homepage


You Must Be Logged In To Post A Comment

Advertise
Increase Your
Brand Awareness
Auctions + Private Sales
Get The
Best Price
Buy Equipment/Parts
Find The
Lowest Price
Daily News
Read The
Latest News
Directory
Browse All
DOTmed Users
Ethics on DOTmed
View Our
Ethics Program
Gold Parts Vendor Program
Receive PH
Requests
Gold Service Dealer Program
Receive RFP/PS
Requests
Healthcare Providers
See all
HCP Tools
Jobs/Training
Find/Fill
A Job
Parts Hunter +EasyPay
Get Parts
Quotes
Recently Certified
View Recently
Certified Users
Recently Rated
View Recently
Certified Users
Rental Central
Rent Equipment
For Less
Sell Equipment/Parts
Get The
Most Money
Service Technicians Forum
Find Help
And Advice
Simple RFP
Get Equipment
Quotes
Virtual Trade Show
Find Service
For Equipment
Access and use of this site is subject to the terms and conditions of our LEGAL NOTICE & PRIVACY NOTICE
Property of and Proprietary to DOTmed.com, Inc. Copyright ©2001-2018 DOTmed.com, Inc.
ALL RIGHTS RESERVED